Laboratory of Translational Genomics
Understanding the contribution of germline genetic variation to cancer etiology and outcomes
The Laboratory of Translational Genomics (LTG) conducts studies on germline and somatic genetics of cancer, and analyses on particular regions of the genome conclusively identified in cancer-specific genome-wide association studies (GWAS) and linkage studies in high-risk families.
LTG's mission is to understand the contribution of germline and somatic genetic variation to cancer etiology and outcomes. Its primary goals are to investigate regions of genetic variation by:
- Detecting cancer susceptibility alleles
- Fine mapping susceptibility alleles using sequence analysis and imputation from public databases
- Prioritizing variants for follow-up studies through bioinformatic analysis of candidate variants
- Deciphering the biological mechanisms underlying susceptibility alleles through laboratory investigation
Learn more about specific LTG research areas.
Essential to the mission of the Laboratory is a close collaboration with the NCI-Frederick Cancer Genomics Research Laboratory (CGR). Formerly known as the Core Genotyping Facility (CGF), this laboratory designs and conducts high throughput sequencing, genotyping, and analysis in support of large scale epidemiologic studies.
Zhang T, Choi J, Kovacs MA, […] Brown KM. Cell-type-specific eQTL of primary melanocytes facilitates identification of melanoma susceptibility genes. Genome Res 2018
Petrovics G, Price DK, Lou H, […] Dean M.Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. Prostate Cancer Prostatic Dis 2018
Zhang M, Lykke-Andersen S, Zhu B, […] Amundadottir L. Characterising cis-regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. Gut 2018
Tang W, Wallace TA, Yi M,[…] Prokunina-Olsson L, Ambs S. IFNL4-ΔG Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer. Clin Cancer Res 2018